BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 25846476)

  • 21. Prevention of damage induced by aspirin in the GI tract.
    Scheiman JM
    Best Pract Res Clin Gastroenterol; 2012 Apr; 26(2):153-62. PubMed ID: 22542153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.
    Martín Merino E; Johansson S; Nagy P; García Rodríguez LA
    Am J Cardiol; 2013 Oct; 112(8):1075-82. PubMed ID: 23831164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice.
    Lanas A
    Expert Opin Drug Saf; 2011 Jan; 10(1):45-54. PubMed ID: 20645883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden.
    Brusselaers N; Lagergren J
    BMJ Open; 2018 Jul; 8(7):e021869. PubMed ID: 29982219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The risk of lower gastrointestinal bleeding in low-dose aspirin users.
    Chen WC; Lin KH; Huang YT; Tsai TJ; Sun WC; Chuah SK; Wu DC; Hsu PI
    Aliment Pharmacol Ther; 2017 Jun; 45(12):1542-1550. PubMed ID: 28449186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
    Saini SD; Fendrick AM; Scheiman JM
    Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
    Sharma T; Bliden K; Chaudhary R; Tantry U; Gurbel PA
    Expert Opin Pharmacother; 2017 Jan; 18(1):123-131. PubMed ID: 27937054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Risk factors for gastrointestinal bleeding associated with low-dose aspirin].
    Sibilia J; Ravaud P; Marck G
    Presse Med; 2003 Nov; 32(37 Pt 2):S9-16. PubMed ID: 14763349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prevalence of co-administration of clopidogrel and proton pump inhibitors.
    Shrestha K; Hughes JD; Lee YP; Parsons R
    Qual Prim Care; 2011; 19(1):35-42. PubMed ID: 21703110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits.
    Lué A; Lanas A
    World J Gastroenterol; 2016 Dec; 22(48):10477-10481. PubMed ID: 28082800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy.
    Casado Arroyo R; Polo-Tomas M; Roncalés MP; Scheiman J; Lanas A
    Heart; 2012 May; 98(9):718-23. PubMed ID: 22523056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Antisecretory Drugs with Upper Gastrointestinal Bleeding in Patients Using Oral Anticoagulants: A Systematic Review and Meta-Analysis.
    Kurlander JE; Barnes GD; Fisher A; Gonzalez JJ; Helminski D; Saini SD; Sengupta N; Yang YX; Scheiman J; Laine L
    Am J Med; 2022 Oct; 135(10):1231-1243.e8. PubMed ID: 35679879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Summaries for patients. Benefits and risks of continuing aspirin in patients with peptic ulcer bleeding.
    Ann Intern Med; 2010 Jan; 152(1):I-20. PubMed ID: 19949137
    [No Abstract]   [Full Text] [Related]  

  • 34. H2 Receptor Antagonists versus Proton Pump Inhibitors in Patients on Dual Antiplatelet Therapy for Coronary Artery Disease: A Systematic Review.
    Almufleh A; Ramirez FD; So D; Le May M; Chong AY; Torabi N; Hibbert B
    Cardiology; 2018; 140(2):115-123. PubMed ID: 29966126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
    Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review.
    Yang M; He M; Zhao M; Zou B; Liu J; Luo LM; Li QL; He JH; Lei PG
    Curr Med Res Opin; 2017 Jun; 33(6):973-980. PubMed ID: 28076696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are Proton Pump Inhibitors More Effective Than Histamine-2-Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients? A Systematic Review and Meta-Analysis of Cohort Studies.
    He N; Yan Y; Su S; Ge Q; Zhai S
    Ann Pharmacother; 2022 Sep; 56(9):988-997. PubMed ID: 34971320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proton pump inhibitors are associated with lower gastrointestinal tract bleeding in low-dose aspirin users with ischaemic heart disease.
    Miyake K; Akimoto T; Hanada Y; Nagoya H; Kodaka Y; Ueki N; Kusunoki M; Kawagoe T; Futagami S; Takahashi Y; Takano H; Sakamoto C
    Dig Liver Dis; 2015 Sep; 47(9):757-62. PubMed ID: 26105589
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.